Join

Compare · MO vs SGTX

MO vs SGTX

Side-by-side comparison of Altria Group Inc. (MO) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MO and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • MO is the larger of the two at $120.55B, about 2072.8x SGTX ($58.2M).
  • MO has hit the wire 17 times in the past 4 weeks while SGTX has been quiet.
  • MO has more recent analyst coverage (19 ratings vs 8 for SGTX).
MetricMOSGTX
Company
Altria Group Inc.
Sigilon Therapeutics Inc.
Price
$72.20+2.24%
$22.53-2.57%
Market cap
$120.55B
$58.2M
1M return
+2.88%
-
1Y return
+22.31%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
17
0
Recent ratings
19
8
MO

Altria Group Inc.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

SGTX

Sigilon Therapeutics Inc.

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Latest MO

Latest SGTX